Lv3
330 积分 2025-03-11 加入
科研小白
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
2个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
2个月前
已完结
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
3个月前
已完结
Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease
3个月前
已关闭
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes
3个月前
已完结
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
3个月前
已完结
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer
3个月前
已完结
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
3个月前
已完结
An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer
3个月前
已完结
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
3个月前
已完结
皖公网安备34019202002308
